This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
SELL NOW!
TheStreet Rating

10 Best Life Sciences Stocks for 2014

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 life sciences stocks are rated highest by our methodology.

Equity Top: Life Sciences Tools & Services


Source: TheStreet Ratings

Best Investments for 2014

Life Sciences

Catch up on Jim Cramer's thinking over the last week about PPG's Mexico deal and the market's amazing run.
11/22/14 2:07PM
Cramer will be listening to conference calls next week but says a lot of the companies are better than their stocks.
11/21/14 8:25PM
The performance of the Nikkei 225 over the last 25 years suggests money printing creates bubbles that eventually break.
11/21/14 2:59PM
The company aims to grow its production by 50% this year, but things could change next year if the price of a barrel of crude averages less than $80.
11/21/14 2:03PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/21/14 6:00AM
The latest example: Reams of wrongheaded hedge-fund short plays off the Ebola crisis.
11/20/14 11:38AM
It's worth paying attention to these potential portfolio killers.
11/20/14 9:55AM
Beijing-based IT superstar Lenovo, despite a record of smooth expansion, stands to lose the most from China's slowdown in smartphone shipments. Here's why.
11/20/14 6:10AM
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.
11/19/14 1:25PM
TheStreet highlights 3 stocks pushing the drugs industry lower today.
11/19/14 12:16PM
TheStreet highlights 3 stocks pushing the drugs industry higher today.
11/19/14 12:16PM
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
11/19/14 11:21AM
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
11/19/14 11:17AM
Housing construction is finally showing signs of recovery, but not because more Americans are buying homes.
11/19/14 10:34AM
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
11/19/14 9:38AM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs